ClinicalTrials.gg
CompletedNCT00334295Updated Jul 31, 2012Results posted

Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.

A Phase 2 interventional study of Fulvestrant in Endometrial Carcinoma, sponsored by AstraZeneca. Completed at 9 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-31.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Endometrial Neoplasms by AstraZeneca — 9 open to participants now, 13 under way, 4 of them phase 3. Endometrial Neoplasms · AstraZeneca.

Enrollment
12th of 12
35 · median 457
Started
2002
the only one that year
Phase 2
2 of 17
1 open now
Registered
1st of 17
by date

Among the 17 studies in Endometrial Neoplasms by AstraZeneca, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2002, is one of 2 in phase 2, and was the 1st registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

9 of the 17 studies in Endometrial Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Endometrial Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy of a monthly administration of Fulvestrant in patients with recurrent or metastatic endometrial carcinoma by assessment of the clinical tumour response after 3 injections.

03

Conditions studied

  • Endometrial Carcinoma

Keywords

  • Recurrent or metastatic endometrial carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, recurrent or endometrial carcinoma
  • Hormonreceptor positive

Exclusion criteria

Exclusion Criteria:

  • Pre-treatment with Fulvestrant
  • Previous endocrine therapy of the endometrial carcinoma
  • Previous less than 3 years ago other than in situ carcinoma of the cervix, basal cell carcinoma or squamous carcinoma of the skin
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Interventions

  • A monthly intramuscular application of 250 mg Fulvestrant as a 1st line endocrine therapy in patients with recurrent or metastatic endometrial carcinoma.

06

What researchers measure

Primary outcomes

  1. Determination (for ITT (Intet-to-Treat Set): Efficacy of a Monthly Administration of Fulvestrant in Patients With Recurrent or Metastatic Endometrial Carcinoma by Assessment of the Clinical Tumour Response After 3 Injections of Fulvestrant

    Number of patients with Complete Remission (CR) and Partial Response (PR), as determined by an independent expert panel according to the WHO response criteria.

    Time frame: up to 1 year

Secondary outcomes

  1. Time to Progression of Disease (TTP-Time To Progression, for ITT Set)

    median TTP

    Time frame: ICF (Informed Consent Form completed) to the date of objective progression or death (by any cause in the absence of progression)

  2. Determination (for ITT Set): Median Survival

    median overall survival (OS)

    Time frame: ICF to the date of death

  3. Determination (All Subjects Treated (AST) Set): Safety and Toxicity by Assessment of the Frequency of Grade I-IV Haematological and Non-haematological Toxicities

    number of adverse events

    Time frame: ICF to Last Patient Out (LPO)

  4. Evaluation (Patient-reported): Change From Baseline in Health-related Quality of Life (HR-QoL) at 12 Months (12 Visits)

    Patient-reported FACT-EN questionaire. Presented is the change from baseline after 12 visits/12 months. The overall total score of 43 single items was transformed to a scale from 0 to 100 (0 = worst level of well-being; 100 = highest level of well-being).

    Time frame: ICF (Baseline) up to 12 months (12 visits)

07

Results

Posted Jul 31, 2012

Participant flow

Participant flow — Overall Study
MilestoneFulvestrant
Started35
Completed30
Not completed5
Withdrew: Patients received fewer than 3 injection5

Outcome measures

PrimaryDetermination (for ITT (Intet-to-Treat Set): Efficacy of a Monthly Administration of Fulvestrant in Patients With Recurrent or Metastatic Endometrial Carcinoma by Assessment of the Clinical Tumour Response After 3 Injections of Fulvestrant

Number of patients with Complete Remission (CR) and Partial Response (PR), as determined by an independent expert panel according to the WHO response criteria.

Time frame:
up to 1 year
Reported as:
Number · participants
Determination (for ITT (Intet-to-Treat Set): Efficacy of a Monthly Administration of Fulvestrant in Patients With Recurrent or Metastatic Endometrial Carcinoma by Assessment of the Clinical Tumour Response After 3 Injections of Fulvestrant
participantsFulvestrant
Determination (for ITT (Intet-to-Treat Set): Efficacy of a Monthly Administration of Fulvestrant in Patients With Recurrent or Metastatic Endometrial Carcinoma by Assessment of the Clinical Tumour Response After 3 Injections of Fulvestrant5
SecondaryTime to Progression of Disease (TTP-Time To Progression, for ITT Set)

median TTP

Time frame:
ICF (Informed Consent Form completed) to the date of objective progression or death (by any cause in the absence of progression)
Reported as:
Median · months
Time to Progression of Disease (TTP-Time To Progression, for ITT Set)
monthsFulvestrant
Time to Progression of Disease (TTP-Time To Progression, for ITT Set)3.1 (2.6 to 6.5)
SecondaryDetermination (for ITT Set): Median Survival

median overall survival (OS)

Time frame:
ICF to the date of death
Reported as:
Median · months
Determination (for ITT Set): Median Survival
monthsFulvestrant
Determination (for ITT Set): Median Survival16.7 (8.6 to 44.4)
SecondaryDetermination (All Subjects Treated (AST) Set): Safety and Toxicity by Assessment of the Frequency of Grade I-IV Haematological and Non-haematological Toxicities

number of adverse events

Time frame:
ICF to Last Patient Out (LPO)
Reported as:
Number · adverse events
Determination (All Subjects Treated (AST) Set): Safety and Toxicity by Assessment of the Frequency of Grade I-IV Haematological and Non-haematological Toxicities
adverse eventsFulvestrant
Determination (All Subjects Treated (AST) Set): Safety and Toxicity by Assessment of the Frequency of Grade I-IV Haematological and Non-haematological Toxicities169
SecondaryEvaluation (Patient-reported): Change From Baseline in Health-related Quality of Life (HR-QoL) at 12 Months (12 Visits)

Patient-reported FACT-EN questionaire. Presented is the change from baseline after 12 visits/12 months. The overall total score of 43 single items was transformed to a scale from 0 to 100 (0 = worst level of well-being; 100 = highest level of well-being).

Time frame:
ICF (Baseline) up to 12 months (12 visits)
Reported as:
Mean · units on a scale
Evaluation (Patient-reported): Change From Baseline in Health-related Quality of Life (HR-QoL) at 12 Months (12 Visits)
units on a scaleFulvestrant
Evaluation (Patient-reported): Change From Baseline in Health-related Quality of Life (HR-QoL) at 12 Months (12 Visits)6.0 ± 1.3-

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fulvestrant———
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventFulvestrant
IleusGastrointestinal disorders2/35
TachycardiaCardiac disorders1/35
Abdominal painGastrointestinal disorders1/35
VomitingGastrointestinal disorders1/35
SubileusGastrointestinal disorders1/35
General physical health deteriorationGeneral disorders1/35
Oedema peripheralGeneral disorders1/35
GastroenteritisInfections and infestations1/35
Wound infectionInfections and infestations1/35
Pain in extremityMusculoskeletal and connective tissue disorders1/35
Most frequent other events
Showing 10 of 27
Most frequent other events
EventFulvestrant
NauseaGastrointestinal disorders9/35
FatigueGeneral disorders8/35
Urinary tract infectionInfections and infestations7/35
DyspnoeaRespiratory, thoracic and mediastinal disorders6/35
Hot flushVascular disorders6/35
Abdominal painGastrointestinal disorders4/35
ConstipationGastrointestinal disorders4/35
DiarrhoeaGastrointestinal disorders4/35
Vaginal haemorrhageReproductive system and breast disorders4/35
VomitingGastrointestinal disorders4/35

Baseline characteristics

Age, Customized
Age, Customized(years)Fulvestrant
Median69.5 (45 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)Fulvestrant
Female35
Male0
08

Study locations

9 sites
  • Research Site
    Erlangen, Germany
  • Research Site
    Göttingen, Germany
  • Research Site
    Halle, Germany
  • Research Site
    Jena, Germany
  • Research Site
    Lübeck, Germany
  • Research Site
    Mainz, Germany
  • Research Site
    Münster, Germany
  • Research Site
    Neunkirchen, Germany
  • Research Site
    Rostock, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2006
First posted
Jun 7, 2006
Start
Dec 2002
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results first posted
Jul 31, 2012
Last update
Jul 31, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00334295
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 7, 2006
Start date
Dec 2002
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
Jul 31, 2012
Last update
Jul 31, 2012

Study contacts

AstraZeneca Germany Medical Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion